MARKERS OF RESPONSE TO CHEMORADIATION IN ESOPHAGEAL CANCER Selection and validation of a panel of markers (MORE-1 and MORE-2)
Completed
- Conditions
- esophageal cancer10017991
- Registration Number
- NL-OMON42549
- Lead Sponsor
- Medisch Centrum Leeuwarden
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 85
Inclusion Criteria
Esophageal cancer with an indication for chemotherapie, radiotherapie with orwithout surgery with curative intention
Exclusion Criteria
Metastatic disease
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The main study parameters are differences in kinetic profile and/or genetic<br /><br>profile between patients with and without a pathologic complete response after<br /><br>chemo radiation.<br /><br><br /><br>Primary endpoint for evaluation in the MORE-1 study is pathologic complete<br /><br>response in the resected material.<br /><br>Primary endpoint for evaluation in the MORE-2 study is survival</p><br>
- Secondary Outcome Measures
Name Time Method <p>Secundary endpoints for evaluation in the MORE-1 study are pathological<br /><br>response, locoregional disease free survival, distant metastasis free survival,<br /><br>disease free survival and survival.<br /><br><br /><br>Secundary endpoints for evaluation in the MORE-2 study are locoregional disease<br /><br>free survival, distant metastasis free survival and disease free survival.</p><br>